PLx Pharma (NASDAQ:PLXP) is scheduled to be releasing its earnings data before the market opens on Friday, November 9th. Analysts expect PLx Pharma to post earnings of ($0.39) per share for the quarter.
PLx Pharma (NASDAQ:PLXP) last released its quarterly earnings data on Friday, August 10th. The biotechnology company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.11. PLx Pharma had a negative return on equity of 169.28% and a negative net margin of 12.57%. The firm had revenue of $0.17 million for the quarter. On average, analysts expect PLx Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
PLXP opened at $3.65 on Wednesday. PLx Pharma has a one year low of $3.05 and a one year high of $7.60. The company has a market capitalization of $31.71 million, a P/E ratio of -1.87 and a beta of 1.68. The company has a debt-to-equity ratio of 0.93, a quick ratio of 9.15 and a current ratio of 9.15.
A number of research firms recently commented on PLXP. ValuEngine cut PLx Pharma from a “hold” rating to a “sell” rating in a report on Wednesday, September 12th. Zacks Investment Research cut PLx Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, July 12th.
TRADEMARK VIOLATION NOTICE: “PLx Pharma (PLXP) to Release Earnings on Friday” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/11/07/plx-pharma-plxp-to-release-earnings-on-friday.html.
PLx Pharma Company Profile
PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics. The company's lead product candidates are Aspertec 81 mg and 325 mg, which are novel formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.
Further Reading: Compound Interest and Why It Matters When Investing
Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.